Superior efficacy with a fixed‐ratio combination of insulin degludec and liraglutide (IDegLira) compared with insulin degludec and liraglutide in insulin‐na?ve Japanese patients with type 2 diabetes in a phase 3, open‐label, randomized trial

摘要

Abstract Aims To investigate the efficacy and safety of insulin degludec/liraglutide (IDegLira) compared with its individual components in Japanese people with type 2 diabetes (T2D) uncontrolled on an oral antidiabetic drug (OAD). Materials and methods This 52‐week, open‐label, multicentre, treat‐to‐target trial randomized participants (n = 819) 1:1:1 to IDegLira, liraglutide 1.8 mg or degludec, as add‐on to their pre‐trial OAD. The maximum IDegLira dose was 50 dose steps (50?U degludec/1.8 mg liraglutide), there was no maximum dose for degludec, and both were titrated based on individual blood glucose measurements. Results After 52?weeks, glycated haemoglobin (HbA1c) decreased by 26?mmol/mol with IDegLira vs 20?mmol/mol with degludec and liraglutide: estimated treatment differences were ?6.91?mmol/mol (95% confidence interval [CI] –8.18; ?5.64) and ?5.30?mmol/mol (95% CI ?6.58; ?4.03), confirming non‐inferiority of IDegLira to degludec and superiority of IDegLira to liraglutide ( P ??.0001 for both [primary endpoint]). Mean body weight changes were 2.9 kg, 4.1 kg and ?1.0 kg with IDegLira, degludec and liraglutide, respectively, showing superiority of IDegLira versus degludec ( P = .0001), but a significant difference in favour of liraglutide ( P ??.0001). Rates of severe or blood glucose‐confirmed hypoglycaemia for IDegLira were lower versus degludec (rate ratio 0.48 [95% CI 0.35; 0.68]; P ??.0001), but higher versus liraglutide (rate ratio 37.58 [95% CI 19.80; 71.31]; P ??.0001). Mean daily total insulin dose was lower with IDegLira (27.7 U) versus degludec (34.8 U; P ??.0001). Overall adverse event (AE) rates were similar. In total, 34.9%, 22.9% and 41.8% of IDegLira‐, degludec‐ and liraglutide‐treated participants experienced gastrointestinal AEs. Conclusion IDegLira was superior to degludec and liraglutide in terms of HbA1c reduction and superior to degludec in terms of body weight change and rates of hypoglycaemia in Japanese people with T2D.